Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Roti patents



      

This page is updated frequently with new Roti-related patent applications.




Date/App# patent app List of recent Roti-related patents
02/04/16
20160030475 
 Use of a clay product or a clay blend product to decrease the effects of bacterial disease in shrimp patent thumbnailUse of a clay product or a clay blend product to decrease the effects of bacterial disease in shrimp
Applicants have examined two clostridium species, clostridium difficile and clostridium perfringens, and found that clays can adsorb the toxin produced by both and that a clay blended product can decrease the effects of a prominent in chickens and known as necrotic enteritis, that is caused by c. Perfringens.
Oil-dri Corporation Of America


02/04/16
20160030472 
 Xenon-based anesthetic gas composition usable during an endarterectomy involving the clamping of the carotid artery patent thumbnailXenon-based anesthetic gas composition usable during an endarterectomy involving the clamping of the carotid artery
A xenon-based anesthetic gas to be used, via inhalation, to maintain or preserve cerebral perfusion during an endarterectomy involving the clamping of the carotid artery in a mammal under general anesthesia. The xenon is preferably used in combination with at least one injectable anesthetic morphine agent such as remifentanil, sulfentanil, fentanyl, and alfentanil.
Air Liquide Santé (international)


02/04/16
20160030153 
 Embolic protection during percutaneous heart valve replacement and similar procedures patent thumbnailEmbolic protection during percutaneous heart valve replacement and similar procedures
Various devices are described to provide filtering of flow from the aorta to the left carotid artery and the right carotid artery. The filters can be brought into a desired position through one or more peripheral arteries.
Lumen Biomedical, Inc.


02/04/16
20160030001 
 Helmet apparatus and system with carotid collar means on-boarded patent thumbnailHelmet apparatus and system with carotid collar means on-boarded
Apparatus for helmeting with carotid collars works in conjunction with a transcranial doppler, phased array photoacoustic device to transmit a first energy to a region of interest at an internal site of a subject to produce an image and blood flow velocities of a region of interest by outputting an optical excitation energy to said region of interest and heating said region, causing a transient thermoelastic expansion and produce a wideband ultrasonic emission. Systems integrate and register the signals for use in, for example, acute stroke care..

01/28/16
20160025743 
 Method for the early detection of renal disease using proteomics patent thumbnailMethod for the early detection of renal disease using proteomics
A method for the detection of an early biomarker for assessing a change in renal status in a mammalian subject following a renal event. The method typically includes the steps of (a) providing a body fluid sample obtained from a mammalian subject; (b) analyzing the molecular weight of the proteins in the sample using proteome analysis; and (c) identifying the presence of a protein in the sample selected from the group consisting of a 6.4 kda protein, a 28.5 kda protein, a 33 kda protein, a 44 kda protein, a 67 kda protein, and combinations thereof.
Children's Hospital Medical Center


01/28/16
20160024577 
 Methods for identifying stem cells based on nuclear morphotypes patent thumbnailMethods for identifying stem cells based on nuclear morphotypes
Methods for identifying stem cells and other cells specific to embryogenesis and carcinogenesis, classifying tissue samples, diagnosing precancerous and cancerous or atherosclerotic lesions, testing the value of anticancer agents, discovering macromolecules specifically expressed in particular cell types, using stem cells in restorative tissue therapy as well as methods for preparing tissue samples so heteromorphic nuclear morphotypes remain intact are disclosed.. .
Massachusettes Institute Of Technology


01/28/16
20160024213 
 Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases patent thumbnailAnti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (mmr) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics.
Vrije Universiteit Brussel


01/28/16
20160023983 
 Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis,skin fibrosis and cardiac fibrosis patent thumbnailSubstituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis,skin fibrosis and cardiac fibrosis
The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein a is c5 alkyl, c6 alkyl, c5 alkenyl, c6 alkenyl, c(o)—(ch2)n—ch3 or ch(oh)—(ch2)n—ch3 wherein n is 3 or 4; r1 is h, oh or f; r2 is h, oh, f or ch2—oh; r3 is h, oh, f or ch2ph; r4 is h, oh or f; q is 1) (ch2)mc(o)oh wherein m is 1 or 2, 2) ch(ch3)c(o)oh, 3) c(ch3)2c(o)oh, 4) ch(f)—c(o)oh, 5) cf2—c(o)oh, or 6) c(o)—c(o)oh.. .
Prometic Biosciences Inc.


01/28/16
20160022377 
 Combined use of ultrasound with nickel titanium endodontic file in endodontic procedure patent thumbnailCombined use of ultrasound with nickel titanium endodontic file in endodontic procedure
The root canal is cleaned by moving the working portion of the file within the root canal so that the working portion of the file cuts or abrades tissue within the root canal. Ultrasonic energy is applied to the file, tooth, or both in order to assist in breaking up and removing necrotic tissue in the root canal during cleaning.

01/21/16
20160015548 
 Patient treatment system patent thumbnailPatient treatment system
A patient treatment system for treating a patient includes a cervical collar having a first opening located over a trachea of the patient and a second opening located over a carotid artery of the patient. An aid is disposed in the second opening and includes a base having a curved surface; the base is disposed proximal to a neck of the patient over the carotid artery.

01/14/16
20160009725 

Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases


In which x, y, n, m, r1, r2, r3, r4 and r5 are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders. Also described is the use of the compounds according to the invention as bet protein inhibitors for benign hyperplasias, for atherosclerotic disorders, for sepsis, for autoimmune disorders, for vascular disorders, for viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for male fertility control..

01/14/16
20160008311 

Oleacein for treating or preventing diseases resulting from atherosclerotic plaques


A description and explanation is provided of the use of oleacein, especially this obtained from ligustrum vulgare l., in the manufacturing of a preparation for the treatment and prevention of diseases that are consequences of the atherosclerotic plaque degradation. Such diseases include in particular those selected from the following group: ischemic brain stroke, heart attack and ischemic heart disease..
Warszawski Uniwersytet Medyczny


01/07/16
20160003808 

Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition


The present invention relates to methods and assays for identifying agents useful in the treatment of diseases associated with epithelial mesenchymal transition (emt), in particular fibrotic diseases and cancer. The invention provides polypeptide and nucleic acid targets, sirna sequences based on these targets and antibodies against the targets.
Galapagos Nv


01/07/16
20160002354 

Antibodies to bone marrow stromal antigen 1


The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd


01/07/16
20160000499 

Endovascular catheters for carotid body ablation utilizing an ionic liquid stream


Methods and endovascular catheters for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via transmural carotid body modulation using a catheter with an ionic liquid stream electrode.. .
Cibiem, Inc.


12/31/15
20150376623 

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof


This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.. .
Isis Pharmaceuticals, Inc.


12/31/15
20150376204 

Alpha helix mimetic compositions for treating cancer and other cbp/catenin-mediated diseases and conditions


Alpha-helix mimetic structures and compounds represented by the formula (i) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed..
Prism Biolab, Co., Ltd.


12/31/15
20150376196 

4-substituted pyrrolo- and pyrazolo-diazepines


Are described, in which x, y, n, m, p, r1, r2, r3, r4 and r5 are each as defined in the description, as are pharmaceutical compositions comprising the inventive compounds, and the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. Also described is the use of the inventive compounds as bet protein inhibitors in benign hyperplasias, in atherosclerotic disorders, in sepsis, in autoimmune disorders, in vascular disorders, in viral infections, in neurodegenerative disorders, in inflammatory disorders and in male fertility control..

12/24/15
20150368262 

Alpha helix mimetics and methods relating thereto


Alpha-helix mimetic structures and compounds represented by the formula (i) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed..
Prism Biolab Co., Ltd.


12/24/15
20150366581 

Percutaneous tools for minimally invasive access to the carotid sheath for vagus nerve stimulation


Various aspects describe a lead delivery system for percutaneous introduction of a lead to a stimulation site near a neural target, such as the vagus nerve for nerve stimulation. The lead delivery system may include a needle assembly having a needle adapted to cut through tissue and provide initial access into the carotid sheath.
Cardiac Pacemakers, Inc.


12/24/15
20150366239 

Production fish feed enriched with polar lipids and method to enrich farmed fishes


The present disclosure relates to the production of fish feed with olive ingredients intended for farmed freshwater and saltwater fish, and the aquaculturing of freshwater and saltwater fish which are fortified or enriched through their feeding with ingredients derived from olive processing byproducts. The invention also relates to the fortified or enriched fish as such.
Nireus Aquaculture S.a


12/17/15
20150360010 

Carotid sheath with entry and tracking rapid exchange dilators and use


Dilators and sheaths for use in minimally invasive vascular therapy are disclosed. In some embodiments, the dilators include a slot that accesses a guidewire lumen within the dilator.
Fischell Innovations, Llc


12/17/15
20150359905 

Composition of anti-endo180 antibodies and methods of use for the treatment of cancer and fibrotic diseases


The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the endo180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the endo180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.. .
Quark Pharmaceuticals, Inc.


12/17/15
20150359848 

Methods and related kits for treating and regenerating tooth pulp and periapical tissues in a mammal


In one embodiment, a method of regenerating tooth pulp in a mammal is provided. The method comprises removing at least a portion the existing tooth pulp of a mammal and adding amelogenin protein to the existing tooth pulp of the mammal to regenerate tooth pulp in a mammal.
University Of Southern California


12/17/15
20150359207 

Animal model for evaluating performance of hemostatic agent for inducing hemorrhage in common carotid artery or superior sagittal sinus, and use thereof


The present invention relates to an animal model for evaluating hemostatic performance, and the use thereof, and more particularly, to an animal model for evaluating the performance of a hemostatic agent, which has hemorrhage induced in the common carotid artery (cca) or superior sagittal sinus (sss) of the animal, a method of screening a hemostatic agent using the animal model, and a method of evaluating the effect of a hemostatic agent using the animal model. The animal model according to the present invention makes it possible to observe the hemostatic effect of a hemostatic agent in a rapid and accurate manner without causing side effects.
Inno Therapy Inc.


12/10/15
20150352065 

Methods of treatment of fibrosis and cancers


The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one for treating fibrotic diseases and cancers.. .
Genfit


12/10/15
20150352038 

A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder


A dosage form for oral administration, via the mucous membranes, of an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder, the active principle being lipophilic or amphiphilic and being in a dissolved state that is stable and complete in a hydro-alcoholic solution having 35% to 70% by weight of ethanol and 30% to 65% by weight of water, generating nanostructures of the active principle under consideration within the hydro-alcoholic solution, thereby enabling the active principle to cross the blood-brain barrier, the active principle being in base and/or salt form and belonging to the chemical families of sleep inducers or modulators of lipophilic or amphiphilic type and of molecular weight that is less than 1000 da, the active principle being selected from the families of imidazopyridines, including zolpidem, the family of cyclopyrrolones, including eszopiclone, the family of pyrazolopyrimidines, including zaleplon, the family of benzodiazepines, including midazolam and brotizolam, the family of h1-antihistamine sedatives, including doxylamine and cyproheptadine, and/or the family of melatonin and melatonin agonists, including melatonin, ramelteon, and agomelatine, the volume of the hydro-alcoholic solution being less than or equal to 2 ml, and the active principle being present at a dosage that is less than or equal to 8 mg, all of the active principle being absorbed in transmucosal manner via the mucous membranes of the floor of the oral cavity, in particular via the gums/cheeks, via the gum area, via the cheeks, or under the tongue.. .

12/10/15
20150351782 

Systems and methods for treating atherosclerotic plaque


A system and method for treating atherosclerotic plaque. The system includes a first catheter including an expandable balloon and a second catheter including a lumen in fluid communication with a distal hole.
Boston Scientific Scimed, Inc.


12/03/15
20150344542 

Partial purification hydrophilic recombinant protein


The present invention relates to a method for partially purifying a hydrophilic recombinant protein from a host expressing a hydrophilic recombinant protein. The method includes: a solution acquisition step in which a dissolving solvent is added to the host expressing a hydrophilic recombinant protein so as to dissolve the host cell and an insoluble substance is separated therefrom so as to obtain a solution.
Spiber Inc.


12/03/15
20150344444 

Bet-protein-inhibiting dihydroxyquinoxalinones


In which a, x, r1, r2, r3, r4, r5, r6, r7 and n are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. This invention further relates to the use of bet protein inhibitors in viral infections, in neurodegenerative disorders, in inflammation disorders, in atherosclerotic disorders and in male fertility control..

12/03/15
20150342966 

Na/k-atpase ligand and uses thereof in wound healing


Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described.. .
The University Of Toledo


11/26/15
20150337037 

Human monoclonal antibodies against human chemokine receptor ccr6


Aspects of this invention include fully human antibodies or fragments thereof that bind specifically to human ccr6 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the ccr6 receptor, including cancers, inflammatory diseases and fibrotic diseases.
Msm Protein Technologies


11/19/15
20150329587 

Extraction hydrophilic recombinant protein


The present invention relates to a method for extracting a hydrophilic recombinant protein from a host expressing a hydrophilic recombinant protein. The method includes: a lysate acquisition step in which a dissolving solvent is added to the host expressing a hydrophilic recombinant protein so as to obtain a host cell lysate; and a step in which a diluting solvent is added to the host cell lysate obtained in the lysate acquisition step, an insoluble substance is separated from the obtained dilution, and a supernatant containing the hydrophilic recombinant protein is collected.
Spiber Inc.


11/19/15
20150328452 

Systems and methods for treating dyspnea, including via electrical afferent signal blocking


Systems and methods for treating a patient with dyspnea are disclosed. A method in accordance with a particular embodiment includes identifying the patient as suffering from dyspnea, and, based at least in part on identifying the patient as suffering from dyspnea, implanting an electrical signal delivery element within the patient in signal communication with an afferent neural pathway of a carotid body chemoreceptor.

11/12/15
20150322082 

Novel compounds as diacylglycerol acyltransferase inhibitors


This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc


11/12/15
20150320904 

Tissue sealant in which collagen and fibrin are mixed, and preparing same


The present invention relates to a tissue sealant in which collagen and fibrin are mixed and to a method for preparing same. To this end, the method of the present invention comprises the steps of: mixing a first material using fibrinogen and aprotinin; mixing a second material using thrombin, calcium chloride, and collagen; and preparing a third material by mixing the first material and the second material.
Sewoncellontec Co., Ltd.


11/12/15
20150320706 

Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy


Administration of a 1-phenylalkanecarboxylic acid before, after, or a concurrently with a therapeutically effective amount of one or more of the following: (1) β-amyloid peptides level reducers, (2) pathogenic level tau reducers, (3) microtubule stabilizers, (4) agents capable or removing atherosclerotic plaques, (5) agents that lower circulating levels of β-amyloid and tau, (6) modulators of autophagy, (7) neurotransmitter levels regulators, (8) gaba(a) α5 receptor antagonists, and (9) additional agents that help maintain and/or restore cognitive function and functional deficits of ad, and/or slow down decline in cognitive functions and functional deficits in ad, is useful for prevention or therapeutical treatment of proteinopathies and/or neurodegenerative diseases.. .
Chiesi Farmaceutici S.p.a.


10/29/15
20150307556 

Template-fixed peptidomimetics with cxcr7 modulating activity


Wherein the single elements t or p are α-amino acid residues connected from the carbonyl (c═o) point of attachment to the nitrogen (n) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor cxcr7. Thus, these β-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilisation of stem cells..

10/29/15
20150306124 

Topical application of ivermectin for the treatment of dermatological conditions/afflictions


Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.. .
Galderma S.a.


10/29/15
20150306027 

Topical application of ivermectin for the treatment of dermatological conditions/afflictions


Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.. .
Galderma S.a.


10/22/15
20150299776 

Identification of a person having risk for atherosclerosis and associated disease by the person's gut microbiome and the prevention of such diseases


The present invention provides the use of metagenomics to identify a compositional or functional alteration of the gut metagenome related to atherosclerosis or atherosclerotic associated disease. Also provided are methods to identify a person having risk for atherosclerosis and associated diseases by determining the presence of specific bacterial groups or species and also metabolic functions in the person's gut microbiota and to use such information to develop a prevention or treatment strategy..
Metabogen Ab


10/22/15
20150299201 

Bet protein-inhibiting 5-aryl triazole azepines


In which r1, r2, r3 and r4 have the meanings given for the general formula (i), to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of bet protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control..

10/22/15
20150299138 

Novel compounds as diacylglycerol acyltransferase inhibitors


This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc


10/22/15
20150297787 

Antimicrobial composition comprising pyrogenic silica and serrathiopeptidase and uses thereof


Methods are provided for treatment of wounds using a complex antimicrobial sorption composition possessing the necrolytic effect for treating the purulent wounds, the trophic ulcers, the wounds, and the infiltrates with the significant necrotic and exudative components represents the silica sorbent with the immobilized drug. Pyrogenic silica is used as a siliceous sorbent, and serrathiopeptidase as a drug..
Willingsford Limited


10/22/15
20150297624 

Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd)


Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd) in humans is disclosed, preferably in hematopoietic stem cell transplantation (hsct), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus host disease of the invention (gvhd) can be acute agvhd and/or chronic cgvhd, preferably acute..
Gentium S.p.a.


10/15/15
20150290142 

Multi-day patch for the transdermal administration of rotigotine


The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention. In addition, the present invention relates to a transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from parkinson's disease, parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome and for use in the treatment or prevention of dopaminergic neuron loss or cognitive disorders by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent-based rotigotine containing self-adhesive matrix layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days..

10/15/15
20150289838 

Systems and methods for real-time assessment of the presence and quantity of carotid blood flow during cardiac arrest


The present technology relates generally to blood flow measuring systems and associated devices and methods. In some embodiments, a system for measuring blood flow during a cardiac arrest configured in accordance with the technology comprises an interface element configured to be removably attached to a patient's skin at a target site proximate to a carotid artery of the patient, a hand-held ultrasound transducer configured to be positioned in contact with the interface element at the target site, and a controller operably coupled to the ultrasound transducer and configured to determine a blood flow velocity of the patient based on received ultrasound data.

10/08/15
20150284345 

Method of preparation of metaxalone


The present invention relates to a method of preparation of metaxalone comprising reaction of triglycidyl isocyanurate (tgic) with m-xylenol, characterized in that said reaction is carried out in a solvent mixture comprising an aprotic polar solvent with dielectric constant greater than or equal to 30 and at least one other solvent selected from the group comprising apolar solvents and aprotic polar solvents with dielectric constant below 30 said solvent mixture comprising from 5 to 40 wt. % of said first solvent and from 95 to 60 wt.

10/08/15
20150283109 

Lipase inhibitors for the treatment of pancreatitis and organ failure


The present invention relates to methods for treating pancreatitis and/or organ failure comprising administering, to a subject in need of such treatment, an effective amount of a lipase inhibitor. It is based, at least in part, on the discoveries that lipotoxicity contributes to inflammation, multisystem organ failure, necrotic pancreatic acinar cell death and in acute pancreatitis, and that inhibition of lipolysis was able to reduce indices associated with these conditions.

10/01/15
20150272754 

Device for deploying a coated stent in the carotid artery


The invention relates to medicine, in particular, to vascular and endovascular surgery. The objective of the invention is to provide accurate positioning of a coated stent in the carotid artery.

10/01/15
20150272612 

Devices and methods for percutaneous endarterectomy


Devices and methods are provided for percutaneously treating atherosclerotic plaques within blood vessels. Atherosclerotic plaques cause significant morbidity and mortality by narrowing the arteries, which adversely affects blood flow, and by acting as a source for thrombi and emboli thus causing acute organ ischemia.
Angioworks Medical B.v.


09/24/15
20150265729 

Rod-shaped plant virus nanoparticles as imaging agent platforms


A rod-shaped plant virus having an interior surface and an exterior surface, and at least one imaging agent that is linked to the interior and/or exterior surface is described. The rod-shaped viruses can be combined into larger spherical nanoparticles.
Case Western Reserve University


09/17/15
20150257779 

Carotid body ablation with a transvenous ultrasound imaging and ablation catheter


Methods and devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation.. .

09/10/15
20150252107 

Aplnr modulators and uses thereof


The present invention provides apelin receptor (aplnr) modulators that bind to aplnr and methods of using the same. The invention includes aplnr modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate aplnr-mediated signaling.
Regeneron Pharmaceuticals, Inc.


09/10/15
20150250855 

Compositions for rapidly treating severe hypoglycemia


Disclosed is a composition for parenteral administration comprising a glucagon peptide which has been dried in a non-volatile glycine buffer, and wherein the glucagon peptide has a ph memory that is about equal to the ph of the glucagon peptide in the non-volatile buffer, wherein the ph memory is between 2.5 to 3.5, an aprotic polar solvent, wherein the peptide is solubilized in the aprotic polar solvent, and wherein the aprotic polar solvent is dimethyl sulfoxide (dmso), trehalose, glycine, and optionally hydrochloric acid, wherein the moisture content of the composition is less than 5 wt. %..
Xeris Pharmaceuticals, Inc.


09/10/15
20150250850 

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome


The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University


09/03/15
20150246910 

Apoptosis signal-regulating kinase inhibitors


Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and are thus useful in the treatment of ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases..

08/27/15
20150238763 

Electrode structures and methods for their use in cardiovascular reflex control


Devices, systems and methods are described by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably reduced by activating baroreceptors. A baroreceptor activation device is positioned near a baroreceptor, preferably a baroreceptor located in the carotid sinus.
Cvrx, Inc.


08/27/15
20150238349 

Therapeutic collar


A therapeutic collar comprising an elongate body made from a flexible material for extending around at least a portion of the neck of a patient. The body has a length approximating the circumference of the neck, two thermoelectric devices for overlying two carotid arteries in the neck and two thermoelectric devices for overlying of two vertebral arteries in the neck when the elongate body is secured around the neck of the patient.
Neuron Guard S.r.l.


08/20/15
20150235570 

Vascular neck restraint training device


A vascular neck restraint training device is used for raining a first person to execute a vascular neck restraint on a second person. The training device includes a supporting structure, such as a collar for being supported about the neck of the second person, upon which a tracheal pressure sensor, and two arterial pressure sensors are supported for alignment with the trachea and the carotid arteries of the second person respectively.

08/20/15
20150232842 

Treatment of fibrotic conditions


Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles.. .
Coda Therapeutics, Inc.


08/20/15
20150230855 

Method of destroying tissue cells by electroporation


An apparatus and method for performing noninvasive treatment of the human face and body by electroporation in lieu of cosmetic surgery is provided. The apparatus comprises a high voltage pulse generator and an applicator having two or more electrodes in close mechanical and electrical, contact with the patient's skin for applying the pulses to the patient's skin.
Angiodynamics, Inc.


08/20/15
20150230774 

Blood pressure monitor and method


A method is provided for noninvasive, continuous, real-time monitoring of a patient's arterial blood pressure using doppler probes and a blood pressure cuff for measurement of a patient's systolic and diastolic blood pressures at a major distal artery. A continuous doppler blood flow velocity measurement is used to generate a waveform signal correlating to a cuff's measurements of systolic and diastolic pressures.

08/13/15
20150224289 

Treatment of renal hypertension or carotid sinus syndrome with adventitial pharmaceutical sympathetic denervation or neuromodulation


Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population.
Mercator Medsystems, Inc.


07/23/15
20150203537 

Inhibition of gliadin peptides


Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation


07/23/15
20150203483 

2,3-benzodiazepines


In which r1a, r1b, r1c, r2, r3, r4, r5, a and x have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of bet protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility..

07/23/15
20150202444 

Systems and methods for selective stimulation of nerve fibers in carotid sinus


An example of a system may include at least one electrode for placement on tissue in a carotid sinus region and a stimulator. The stimulator may be configured to use the at least one electrode to deliver neural stimulation to a baroreceptor region or at least one nerve innervating the baroreceptor region in the carotid sinus region to elicit a baroreflex response, and to deliver a blocking stimulation to a carotid body or at least one nerve innervating the carotid body in the carotid sinus region to inhibit a chemoreceptor response, the stimulator configured to simultaneously deliver the neural stimulation and the blocking stimulation..
Cardiac Pacemakers, Inc.


07/23/15
20150202260 

Endoglin peptides to treat fibrotic diseases


In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (eng) polypeptide may be used to treat fibrotic disorders.. .
Acceleron Pharma, Inc.


07/16/15
20150197603 

Process for the preparation of polyquarternium-l


The present invention relates to a method for the preparation of polyquaternium-1, wherein an aprotic polar solvent is used as the reaction medium, and a solid polyquaternium-1 having a low degree of polydispersity.. .
Alfred E. Tiefenbacher (gmbh & Co. Kg)


07/16/15
20150196580 

Use of defibrotide for the inhibition of heparanase


A study has been carried out to verify the effect of defibrotide on the activity and expression of heparanase enzyme on myeloma tumor cells (u266) and human microvascular endothelial cells (hmec). The study has demonstrated that defibrotide can be effectively used for the manufacture of a medicament for the treatment of diseases which are positively affected by the inhibition of heparanse and/or by the downregulation of heparanse gene expression, such as diabetes..
Gentium Spa


07/09/15
20150190267 

Patient treatment system


A patient treatment system for treating a patient includes a cervical collar having a first opening located over a trachea of the patient and a second opening located over a carotid artery of the patient. An aid is disposed in the second opening and includes a base having a curved surface; the base is disposed proximal to a neck of the patient over the carotid artery.
Medical Science Technologies Llc






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Roti for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roti with additional patents listed. Browse our RSS directory or Search for other possible listings.


5.4674

4995

4 - 0 - 101